Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.77 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.71 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.71 |
| ▸ | ITGAL | P20701 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481399 | 1.00 | KDM4E (0.77) | KDM4EITGB2ICAM1ITGALKMT2A | |
| SCHEMBL5476029 | 0.87 | MAPT (0.76) | KDM4EITGB2ICAM1ITGALKMT2A | |
| SCHEMBL5476034 | 0.87 | MAPT (0.76) | KDM4EITGB2ICAM1ITGALKMT2A | |
| SCHEMBL7621845 | 0.84 | ITGAL (1.00) | KDM4EITGB2ICAM1ITGALKMT2A | |
| SCHEMBL5830899 | 0.84 | ITGAL (1.00) | KDM4EITGB2ICAM1ITGALKMT2A | |
| SCHEMBL27475322 | 0.84 | KDM4E (0.69) | KDM4EITGB2ICAM1ITGALKMT2A | |
| SCHEMBL5476919 | 0.83 | TRPA1 (0.60) | KDM4EITGB2ICAM1ITGALKMT2A | |
| SCHEMBL5476924 | 0.83 | TRPA1 (0.60) | KDM4EITGB2ICAM1ITGALKMT2A | |
| SCHEMBL27473974 | 0.83 | ITGB2 (0.92) | KDM4EITGB2ICAM1ITGALKMT2A | |
| SCHEMBL5477034 | 0.81 | KDM4E (0.52) | KDM4EITGB2ICAM1ITGALKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | claimed |
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049578-A1 | Cinnamamide compounds as metabotropic glutamate receptor antagonists | GRM5, GRM1, GRM3 | KDM4E 1679/4885ITGB2 4496/4885ICAM1 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.